Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes

Diabetes, Obesity and Metabolism

Volumn 19, Issue 7, 2017, Pages 1032-1039

  Heise, Tim ^a   Nørskov, Marianne ^b   Nosek, Leszek ^a   Kaplan, Kadriye ^b   Famulla, Susanne ^a   Haahr, Hanne L ^b  

^a Profil   (Germany)

^b NOVO NORDISK A S   (Denmark)

Author keywords

insulin analogues; insulin therapy; pharmacodynamics; type 1 diabetes

Indexed keywords

GLUCOSE; INSULIN DEGLUDEC; INSULIN GLARGINE; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; LONG ACTING INSULIN;

ADULT; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; ANALYSIS; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; HYPERGLYCEMIA; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; REPRODUCIBILITY;

ADULT; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLYCATED HEMOGLOBIN A; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN GLARGINE; INSULIN RESISTANCE; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS;

EID: 85018869348     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12938     Document Type: Article

References (19)

1. Rossetti P, Ampudia-Blasco FJ, Ascaso JF. Old and new basal insulin formulations: understanding pharmacodynamics is still relevant in clinical practice. Diabetes Obes Metab. 2014;16:695-706.
2. Heise T, Mathieu C. Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Diabetes Obes Metab. 2017;19(1):3-12.
3. Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014;53(9):787-800.
4. Heise T, Nosek L, Rønn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53:1614-1620.
5. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14(9):859-864.
6. Heise T, Hövelmann U, Nosek L, Hermanski L, Bøttcher SG, Haahr H. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. Expert Opin Drug Metab Toxicol. 2015;11(8):1193-1201.
7. Becker RH, Dahmen R, Bergmann K, Lehmann A, Jax T, Heise T. New insulin glargine 300 units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1. Diabetes Care. 2015;38(4):637-643.
8. Seested T, Burgess A, Pyke C, Nishimura E. Ultrastructural 3D visualization of insulin degludec multihexamers upon subcutaneous injection in pig. Diabetes. 2016;65(suppl 1):A236(Poster 918-P).
9. Becker R, Hahn A, Boderke P, et al. Long-acting formulations of insulins. European Patent Office. 2011. https://data.epo.org/publication-server/rest/v1.0/publication-dates/20111123/patents/EP2387989NWA2/document.pdf. Accessed December 13, 2016.
10. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36(5):1384-1395.
11. Food and Drug Administration. Toujeo® SoloSTAR® (Insulin glargine recombinant) 300 units/ml. U.S. Label information, 25 February 2015. http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206538. Accessed December 13, 2016.
12. Bolli GB, Perriello G, Fanelli CG, De Feo P. Nocturnal blood glucose control in type I diabetes mellitus. Diabetes Care. 1993;16(suppl 3):71-89.
13. Heise T, Nosek L, Bottcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14(10):944-950.
14. Toujeo® 300 units/ml solution for injection in a pre-filled pen. EU Summary of Product Characteristics (SmPC), 17 February 2015. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000309/WC500047935.pdf. Accessed December 13, 2016.
15. Porcellati F, Bolli GB, Fanelli CG. Pharmacokinetics and pharmacodynamics of basal insulins. Diabetes Technol Ther. 2011;13(suppl 1):S15-S24.
16. Heise T, Zijlstra E, Nosek L, Heckermann S, Plum-Mörschel L, Forst T. Euglycaemic glucose clamp: what it can and cannot do, and how to do it. Diabetes Obes Metab. 2016;18(10):962-972.
17. Benesch C, Heise T, Klein O, Heinemann L, Arnolds S. How to assess the quality of glucose clamps? Evaluation of clamps performed with ClampArt, a novel automated clamp device. J Diabetes Sci Technol. 2015;9(4):792-800.
18. Lane WS, Bailey TS, Gerety G, et al. Switch 1: reduced hypoglycemia with insulin degludec (IDeg) vs insulin glargine (IGlar) in patients with T1D at high risk of hypoglycemia: a randomized, double-blind, crossover trial. Diabetes. 2016;65(suppl 1A):87-LB.
19. Wysham C, Bhargava A, Chaykin L, et al. SWITCH 2: reduced hypoglycemia with insulin degludec (IDeg) versus insulin glargine (IGlar), both U100, in patients with T2D at high risk of hypoglycemia: a randomized, double-blind, crossover trial. Diabetes. 2016;65(suppl 1A):90-LB.